1) Pharma 2020 : The Vision, PriceWaterHouseCoopers (PwC), 2007
2) DiMasi JA, Hansen RW, Grabowski HG. The price of innovation : new estimates of drug development costs. J Health Econ. 2003 Mar ; 22 (2) : 151-85.
3) Food and Drug Administration. FDA Critical Path Initiatives white paper : innovation or stagnation? Challenge and opportunity on the critical path to new medical products (http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html) (2004).